A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs RX 5902 (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 04 May 2017 According to a Rexahn Pharmaceuticals media release, clinical readout from the study is anticipated towards the end of the year 2017.
    • 04 Oct 2016 According to a Rexahn Pharmaceuticals media release, data from this trial will be presented at the 2016 European Society for Medical Oncology (ESMO) Congress.
    • 07 Jun 2016 Interim results (n=18) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top